(Q37511121)

English

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

scientific article published on 16 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

author name string

Leonardo Magro

1

1 reference

Europe PubMed Central

20 August 2017

Mohamad Mohty

2

1 reference

Europe PubMed Central

20 August 2017

Benoit Catteau

3

1 reference

Europe PubMed Central

20 August 2017

Valérie Coiteux

4

1 reference

Europe PubMed Central

20 August 2017

Patrice Chevallier

5

1 reference

Europe PubMed Central

20 August 2017

Louis Terriou

6

1 reference

Europe PubMed Central

20 August 2017

Jean-Pierre Jouet

7

1 reference

Europe PubMed Central

20 August 2017

Ibrahim Yakoub-Agha

8

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

16 March 2009

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

114

1 reference

Europe PubMed Central

20 August 2017

3

1 reference

Europe PubMed Central

20 August 2017

719-722

1 reference

Europe PubMed Central

20 August 2017

A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

The management and outcome of chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

26 June 2018

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic graft versus host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current management of GIST

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-02-204750

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37511121&oldid=2104421189"